Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05594043 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT05594043 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 90 participants.
The verdict
NCT05594043, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG MK-6598
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2025-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05594043
The ClinicalTrials.gov registry entry for NCT05594043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05594043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05594043 about?
NCT05594043 is a clinical study titled "A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)". The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors.
What is the current status of trial NCT05594043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-12-21. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT05594043?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-6598 (DRUG).
Who is sponsoring clinical trial NCT05594043?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.